• Something wrong with this record ?

Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study

SEV. Cook, K. Menšíková, D. Koníčková, H. Šlanhofová, K. Klíčová, M. Raška, J. Zapletalová, D. Friedecký, P. Kaňovský

. 2025 ; 132 (6) : 811-826. [pub] 20250303

Language English Country Austria

Document type Journal Article, Comparative Study

Persistent link   https://www.medvik.cz/link/bmc25015545

While diagnostic criteria have been established and validated for most neurodegenerative diseases, the considerable overlap between individual nosological entities remains a significant diagnostic challenge. Increasing evidence suggests that neurodegeneration is often initiated by inflammation within the central nervous system. The identification of inflammation could serve as a first signal of the pathophysiological process. As such, validated biological markers ("biomarkers") of neuroinflammation are critically important. This study aimed to assess the presence and levels of inflammatory biomarkers in three neurodegenerative diseases: Lewy body diseases (LBD), multiple system atrophy (MSA), and 4-repeat tauopathies (4RT). A total of 83 LBD, 24 MSA, and 31 4RT patients were included, with 83 control subjects for comparison. Six immune-related proteins were analysed in cerebrospinal fluid (CSF) and blood serum (serum): C3 complement, C4 complement, haptoglobin, transferrin, orosomucoid, and β2 microglobulin (β2M). ANCOVA statistical analysis revealed significantly lower levels of several inflammatory biomarkers in LBD (CSF: transferrin, C3 complement, orosomucoid; Serum: orosomucoid, β2M) and MSA (CSF: transferrin, C3 complement, C4 complement, orosomucoid) compared to controls. Significant differences were also observed between the synucleinopathy patient groups (LBD and MSA) and 4RT in serum levels of C3 complement. Additionally, the CSF/serum quotients for transferrin (LBD and MSA) and C3 complement (LBD) were significantly lower in disease relative to controls. These findings suggest that inflammatory processes may play a role in the pathophysiology of neurodegenerative proteinopathies, warranting further research to confirm these associations. The identification of potential fluid biomarkers would then represent a promising step forward in the field.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015545
003      
CZ-PrNML
005      
20250731091050.0
007      
ta
008      
250708s2025 au f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00702-025-02902-6 $2 doi
035    __
$a (PubMed)40029428
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a au
100    1_
$a Cook, Sarah E V $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. sarah.cook01@upol.cz $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic. sarah.cook01@upol.cz $1 https://orcid.org/000000024389947X
245    10
$a Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study / $c SEV. Cook, K. Menšíková, D. Koníčková, H. Šlanhofová, K. Klíčová, M. Raška, J. Zapletalová, D. Friedecký, P. Kaňovský
520    9_
$a While diagnostic criteria have been established and validated for most neurodegenerative diseases, the considerable overlap between individual nosological entities remains a significant diagnostic challenge. Increasing evidence suggests that neurodegeneration is often initiated by inflammation within the central nervous system. The identification of inflammation could serve as a first signal of the pathophysiological process. As such, validated biological markers ("biomarkers") of neuroinflammation are critically important. This study aimed to assess the presence and levels of inflammatory biomarkers in three neurodegenerative diseases: Lewy body diseases (LBD), multiple system atrophy (MSA), and 4-repeat tauopathies (4RT). A total of 83 LBD, 24 MSA, and 31 4RT patients were included, with 83 control subjects for comparison. Six immune-related proteins were analysed in cerebrospinal fluid (CSF) and blood serum (serum): C3 complement, C4 complement, haptoglobin, transferrin, orosomucoid, and β2 microglobulin (β2M). ANCOVA statistical analysis revealed significantly lower levels of several inflammatory biomarkers in LBD (CSF: transferrin, C3 complement, orosomucoid; Serum: orosomucoid, β2M) and MSA (CSF: transferrin, C3 complement, C4 complement, orosomucoid) compared to controls. Significant differences were also observed between the synucleinopathy patient groups (LBD and MSA) and 4RT in serum levels of C3 complement. Additionally, the CSF/serum quotients for transferrin (LBD and MSA) and C3 complement (LBD) were significantly lower in disease relative to controls. These findings suggest that inflammatory processes may play a role in the pathophysiology of neurodegenerative proteinopathies, warranting further research to confirm these associations. The identification of potential fluid biomarkers would then represent a promising step forward in the field.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a biologické markery $x krev $x mozkomíšní mok $7 D015415
650    12
$a multisystémová atrofie $x krev $x mozkomíšní mok $7 D019578
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a demence s Lewyho tělísky $x krev $x mozkomíšní mok $7 D020961
650    12
$a tauopatie $x krev $x mozkomíšní mok $7 D024801
650    12
$a neurozánětlivé nemoci $x krev $x mozkomíšní mok $7 D000090862
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Menšíková, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Koníčková, Dorota $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Šlanhofová, Hedvika $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Klíčová, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Raška, Milan $u Department of Immunology, University Hospital Olomouc, Olomouc, Czech Republic $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Zapletalová, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Friedecký, David $u Department of Clinical Biochemistry, University Hospital Olomouc, Olomouc, Czech Republic $u Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Kaňovský, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic
773    0_
$w MED00010058 $t Journal of neural transmission $x 1435-1463 $g Roč. 132, č. 6 (2025), s. 811-826
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40029428 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091044 $b ABA008
999    __
$a ok $b bmc $g 2366410 $s 1252670
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 132 $c 6 $d 811-826 $e 20250303 $i 1435-1463 $m Journal of neural transmission $n J Neural Transm (Vienna) $x MED00010058
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options